Guided Therapeutics Inc Watch

from S-1/A 41 pages Shares of Common Stock, Pre-Funded Warrants (Exercisable for Shares) and Common Warrants (Exercisable for Shares) of Guided Therapeutics, Inc. Underwriting Agreement

from S-1/A 40 pages Shares of Common Stock, Pre-Funded Warrants (Exercisable for Shares) and Common Warrants (Exercisable for Shares) of Guided Therapeutics, Inc. Underwriting Agreement

from 8-K/A 5 pages The Unaudited Pro Forma Financial Information Has Been Prepared by the Management of Spectrx Based on the Historical Financial Statements of Spectrx the Unaudited Pro Forma Combined Condensed Financial Information Is Prepared for Informational Purposes Only and Is Not Necessarily Indicative of Future Results or of Actual Results That Would Have Been Achieved Had the Sale Been Consummated at the Beginning of the Periods Presented, Nor Is It Indicative of Future Financial Position or Results of Operations

from 8-K 1 page Spectrx, Inc. to Reschedule First Quarter Operating Results and Conference Call

from 8-K 29 pages Asset Purchase Agreement

from 8-K ~5 pages Spectrx Reports Fourth Quarter and Year-End 2002 Results

from 8-K 1 page Spectrx, Inc. Sells Bilichek(r) Product Line to Respironics

from 8-K 1 page Spectrx, Inc. Seeks to Terminate Continuous Glucose Monitoring Development Agreement With Abbott Laboratories Spectrx Moves for a Faster Path to Commercialization

from 8-K 13 pages Agreement for Termination of Development and Commercialization Agreement

from 8-K 1 page Spectrx, Inc. to Trade on NASDAQ Smallcap Market

from 8-K 1 page Underwriting agreement

from SC 13D/A 1 page Portions of This Document Have Been Omitted (Designated by an Asterisk (*)) and Filed Separately With the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment Dated September 14, 2001. September 4, 2001 via Facsimile Mr. Mark Samuels Chairman & CEO Spectrx, Inc. 6025 a Unity Drive Norcross, Ga 30071 Re: Amendment to the Research & Development License Agreement (October 10, 1996) as Previously Amended by the Parties ("Rdl Agreement") Dear Mark: In Accordance With Our Recent Discussions, Abbott Hereby Delivers the Development Program Notification to Spectrx Pursuant to the Rdl Agreement, and Abbott and Spectrx (The "Parties") Hereby Amend the Terms of the Rdl Agreement as Follows

from SC 13D/A ~5 pages Underwriting agreement

from SC 13D/A ~5 pages Underwriting agreement

from SC 13D/A 1 page Underwriting agreement

from SC 13D 1 page Underwriting agreement

from S-1/A ~50 pages Form of Underwriting Agreement

from S-1 ~50 pages Form of Underwriting Agreement